Patents Assigned to ONTARIO INSTITUTE FOR CANCER RESEARCH (OICR)
-
Publication number: 20240018600Abstract: There is described herein a method of prognosing and/or predicting disease progression and/or in subject with prostate cancer, the method comprising: a) providing a sample containing mitochondrial genetic material from prostate cancer cells; b) sequencing the mitochondrial genetic material with respect to at least 1 patient biomarker selected from CSB1, OHR, ATP8 and HV1 (hypervariable region 1); c) comparing the sequence of said patient biomarkers to control or reference biomarkers to determine mitochondrial single nucleotide variations (mtSNVs); and d) determining the a prostate cancer prognosis; wherein a relatively worse outcome is associated with the presence of mtSNVs in CSB1, OHR, ATP8 and a relatively better outcome is associated with the presence of mtSNVs in HV1.Type: ApplicationFiled: November 14, 2022Publication date: January 18, 2024Applicants: Ontario Institute for Cancer Research (OICR), UNIVERSITY HEALTH NETWORKInventors: Julia A. HOPKINS, Paul Boutros, Robert G. BRISTOW
-
Patent number: 11576981Abstract: The present application is directed to compounds of Formula (I)-(VIII): compositions comprising these compounds and their uses, for example as medicaments and/or diagnostics.Type: GrantFiled: December 6, 2018Date of Patent: February 14, 2023Assignee: ONTARIO INSTITUTE FOR CANCER RESEARCH (OICR)Inventors: Rima Al-awar, Andrew Zhang, Ahmed Mamai
-
Patent number: 11566292Abstract: There is described herein a method of prognosing endocrine-only treatment in a subject with breast cancer, the method comprising: a) providing a tumor sample of the breast cancer; b) determining the expression level of at least 40 of the genes listed in Table 4 in the tumor sample; c) comparing said expression levels to a reference expression level of the group of genes from control samples from a cohort of subjects; and d) determining the residual risk associated with the breast cancer; wherein a statistically significant difference or similarity in the expression of the group of genes compared to the reference expression level corresponds to a residual risk associated with breast cancer.Type: GrantFiled: December 7, 2016Date of Patent: January 31, 2023Assignee: ONTARIO INSTITUTE FOR CANCER RESEARCH (OICR)Inventors: Jane Bayani, John M. S. Bartlett, Cindy Q. Yao, Paul C. Boutros
-
Patent number: 11518764Abstract: The present application relates to compounds of Formula I or pharmaceutically acceptable salts, solvates and/or prodrugs thereof, to compositions comprising these compounds or pharmaceutically acceptable salts, solvates and/or prodrugs thereof, and various uses in the treatment of diseases, disorders or conditions that are treatable by inhibiting interactions with BCL6 BTB, such as cancer.Type: GrantFiled: February 6, 2019Date of Patent: December 6, 2022Assignee: ONTARIO INSTITUTE FOR CANCER RESEARCH (OICR)Inventors: Rima Al-awar, Methvin Isaac, Anh My Chau, Ahmed Mamai, Iain Watson, Gennady Poda, Pandiaraju Subramanian, Brian Wilson, David Uehling, Michael Prakesch, Babu Joseph, Justin-Alexander Morin
-
Patent number: 11505539Abstract: The present application relates to compounds of Formula I (I) or pharmaceutically acceptable salts, solvates and/or prodrugs thereof, to compositions comprising these compounds or pharmaceutically acceptable salts, solvates and/or prodrugs thereof, and various uses in the treatment of diseases, disorders or conditions that are treatable by inhibiting interactions with BCL6 BTB and/or by degrading BCL6, such as cancer.Type: GrantFiled: December 21, 2018Date of Patent: November 22, 2022Assignee: Ontario Institute for Cancer Research (OICR)Inventors: Methvin Isaac, Anh My Chau, Ahmed Mamai
-
Patent number: 11364234Abstract: The present application relates to the treatment of nematode infections.Type: GrantFiled: September 10, 2019Date of Patent: June 21, 2022Assignees: The Governing Council of the University of Toronto, Ontario Institute for Cancer Research (OICR)Inventors: Peter Roy, Sean Harrington, Jacob Pyche, Daniel Kulke, Genna M. Luciani, Andrew Burns, Mark Lautens, Rachel Ross, David Uehling
-
Patent number: 11242351Abstract: The present application relates to compounds of Formula (I) or pharmaceutically acceptable salts, solvates and/or prodrugs thereof, to compositions comprising these compounds or pharmaceutically acceptable salts, solvates and/or prodrugs thereof, and various uses in the treatment of diseases, disorders or conditions that are treatable by inhibiting interactions with BCL6 BTB, such as cancer.Type: GrantFiled: December 21, 2018Date of Patent: February 8, 2022Assignee: ONTARIO INSTITUTE FOR CANCER RESEARCH (OICR)Inventors: Rima Al-awar, Methvin Isaac, Anh My Chau, Ahmed Mamai, Iain Watson, Gennady Poda, Pandiaraju Subramanian, Brian Wilson, David Uehling
-
Patent number: 11192880Abstract: The present application relates to compounds of Formula I or pharmaceutically acceptable salts, solvates and/or prodrugs thereof, to compositions comprising these compounds or pharmaceutically acceptable salts, solvates and/or prodrugs thereof, and various uses in the treatment of diseases, disorders or conditions that are treatable by inhibiting interactions with BCL6 BTB and/or by degrading BCL6, such as cancer.Type: GrantFiled: December 20, 2018Date of Patent: December 7, 2021Assignee: ONTARIO INSTITUTE FOR CANCER RESEARCH (OICR)Inventors: Methvin Isaac, Anh My Chau
-
Patent number: 11015226Abstract: There is provided herein a method for determining a likelihood of resistance to anthracyclin, or poor survival, in a patient with cancer by identifying upregulation of at least one histone gene in the patient.Type: GrantFiled: October 4, 2016Date of Patent: May 25, 2021Assignee: ONTARIO INSTITUTE FOR CANCER RESEARCH (OICR)Inventors: Melanie Spears, John M. Bartlett, Marsela Braunstein, Paul M. Krzyzanowski, Irina Kalatskaya, Lincoln Stein
-
Publication number: 20210106694Abstract: The present application is directed to compounds of Formula (I): compounds of Formula (II): compounds of Formula (III): and compounds of Formula (IV): compositions comprising these compounds and their uses, for example as medicaments and/or diagnostics. Specifically claimed are: (1) compounds containing reactive functional groups (compound of formula I), compounds containing compounds to be linked together (compound of formula II) and compounds having a reactive functional group/a compound to be linked (compound of formula IV), (2) an antibody-drug conjugate (compound of formula III), wherein the antibody is covalently attached by a linker to one or more drugs, (3) pharmaceutical compositions comprising compounds of Formula (II) or Formula (III), (4) treatment/diagnosis of disease comprising compounds of Formula (II) or Formula (III), and (5) methods of preparing an ADC of Formula III.Type: ApplicationFiled: December 20, 2018Publication date: April 15, 2021Applicant: Ontario Institute for Cancer Research (OICR)Inventors: Rima Al-awar, Ahmed Mamai
-
Publication number: 20210053978Abstract: The present application relates to compounds of Formula (I) or pharmaceutically acceptable salts, solvates and/or prodrugs thereof, to compositions comprising these compounds or pharmaceutically acceptable salts, solvates and/or prodrugs thereof, and various uses in the treatment of diseases, disorders or conditions that are treatable by inhibiting interactions with BCL6 BTB, such as cancer.Type: ApplicationFiled: December 21, 2018Publication date: February 25, 2021Applicant: Ontario Institute for Cancer Research (OICR)Inventors: Rima Al-awar, Methvin Isaac, Anh My Chau, Ahmed Mamai, Iain Watson, Gennady Poda, Pandiaraju Subramanian, Brian Wilson, David Uehling
-
Publication number: 20200397916Abstract: The present application is directed to compounds of Formula (I)-(VI): (I), (II), (III), (IV), (V) (VI), (VII) and (VIII), compositions comprising these compounds and their uses, for example as medicaments and/or diagnostics.Type: ApplicationFiled: December 6, 2018Publication date: December 24, 2020Applicant: Ontario Institute for Cancer Research (OICR)Inventors: Rima Al-Awar, Andrew Zhang, Ahmed Mamai
-
Publication number: 20200331921Abstract: The present application relates to compounds of Formula I (I) or pharmaceutically acceptable salts, solvates and/or prodrugs thereof, to compositions comprising these compounds or pharmaceutically acceptable salts, solvates and/or prodrugs thereof, and various uses in the treatment of diseases, disorders or conditions that are treatable by inhibiting interactions with BCL6 BTB, such as cancer.Type: ApplicationFiled: February 6, 2019Publication date: October 22, 2020Applicant: Ontario Institute for Cancer Research (OICR)Inventors: Rima Al-awar, Methvin Isaac, Anh My Chau, Ahmed Mamai, Lain Watson, Gennady Poda, Pandiaraju Subramanian, Brian Wilson, David Uehling, Michael Prakesch, Babu Joseph, Justin-Alexander Morin
-
Publication number: 20200325119Abstract: The present application relates to compounds of Formula I or pharmaceutically acceptable salts, solvates and/or prodrugs thereof, to compositions comprising these compounds or pharmaceutically acceptable salts, solvates and/or prodrugs thereof, and various uses in the treatment of diseases, disorders or conditions that are treatable by inhibiting interactions with BCL6 BTB and/or by degrading BCL6, such as cancer.Type: ApplicationFiled: December 20, 2018Publication date: October 15, 2020Applicant: Ontario Institute for Cancer Research (OICR)Inventors: Methvin Isaac, Anh My Chau
-
Publication number: 20200308147Abstract: The present application relates to compounds of Formula I (I) or pharmaceutically acceptable salts, solvates and/or prodrugs thereof, to compositions comprising these compounds or pharmaceutically acceptable salts, solvates and/or prodrugs thereof, and various uses in the treatment of diseases, disorders or conditions that are treatable by inhibiting interactions with BCL6 BTB and/or by degrading BCL6, such as cancer.Type: ApplicationFiled: December 21, 2018Publication date: October 1, 2020Applicant: Ontario Institute for Cancer Research (OICR)Inventors: Methvin Isaac, Anh My Chau, Ahmed Mamai
-
Publication number: 20150294062Abstract: A method for identifying a target molecular profile associated with a target cell population. A set of reference molecular profiles and a set of sample molecular profiles are received. Each sample molecular profile is associated with a sample cell from a sample cell population, which includes a mixture of target cells and reference cells. Each of the sample molecular profiles is indicative of a respective target molecular profile. An average target molecular profile is calculated. A proportion value is calculated for each sample molecular profile. A respective target molecular profile is calculated for each sample molecular profile based on the respective calculated proportion value and a closest similarity to the average target molecular profile.Type: ApplicationFiled: October 29, 2013Publication date: October 15, 2015Applicant: ONTARIO INSTITUTE FOR CANCER RESEARCH (OICR)Inventors: Gerald Quon, Syed Haider, Ang Cui, Paul C. Boutros, Quaid D. Morris